GlassScriptPhysician profile
Atif Khan
NPI 1225097041
$13,705.95
in general payments reported to CMS, 2019-2025
55 companies · $2,024 in 2025
The $2,024 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,976 · 2020: $463 · 2021: $2,130 · 2022: $2,459 · 2023: $2,630 · 2024: $2,023 · 2025: $2,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,463 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,462.76 |
| Education | $214.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,028.64 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $988.83 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Merck Sharp & Dohme LLC | $963.54 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $922.47 | 2019-2025 | |
| Abbvie INC. | $905.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $606.46 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $518.01 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Daiichi Sankyo INC. | $506.49 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Gilead Sciences, INC. | $428.86 | 2019-2025 | Trodelvy |
| Genzyme Corporation | $414.15 | 2019-2024 | |
| Janssen Biotech, INC. | $398.37 | 2019-2025 | Rybrevant, Tecvayli, Erleada |
| Eisai INC. | $381.69 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $373.20 | 2019-2025 | Opdivo, Opdualag |
| Seagen INC. | $369.76 | 2021-2025 | Tukysa, Padcev |
| Rigel Pharmaceuticals, INC. | $353.19 | 2019-2024 | Rezlidhia, Tavalisse |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $290.46 | 2021-2025 | Onivyde, Tazverik, Somatuline Depot |
| Exelixis INC. | $284.59 | 2019-2025 | Cabometyx |
| Lilly USA, LLC | $278.00 | 2019-2024 | Verzenio, Jaypirca |
| Astellas Pharma US INC | $259.89 | 2019-2025 | Padcev, Vyloy, Xtandi |
| Adc Therapeutics America, INC. | $250.14 | 2021-2024 | |
| Genentech USA, INC. | $204.50 | 2019-2024 | Tecentriq, Alecensa, Venclexta |
| Beigene USA, INC. | $199.05 | 2021-2025 | Brukinsa |
| Array Biopharma INC | $179.57 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| Myovant Sciences INC. | $170.09 | 2021-2022 | |
| Puma Biotechnology, INC. | $164.66 | 2019-2025 | |
| Emd Serono, INC. | $163.04 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $159.80 | 2019-2025 | Libtayo |
| Celgene Corporation | $149.51 | 2019-2024 | Opdualag, Reblozyl |
| Sumitomo Pharma America, INC. | $135.05 | 2023 | Orgovyx |
| Karyopharm Therapeutics INC. | $134.50 | 2021-2025 | Xpovio |
| Pharmacosmos Therapeutics INC. | $128.76 | 2023-2025 | Monoferric, Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $111.59 | 2019-2025 | Ninlaro |
| Pharmacyclics LLC, An Abbvie Company | $107.65 | 2019-2022 | |
| Morphosys, US INC. | $103.58 | 2021-2023 | Monjuvi |
| Myriad Genetic Laboratories, INC. | $103.23 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $102.44 | 2019-2025 | |
| Beone Medicines USA, INC. | $89.50 | 2025 | Brukinsa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.34 | 2021-2024 | Gilotrif |
| Aveo Pharmaceuticals, INC. | $75.01 | 2022-2025 | |
| Mirati Therapeutics, INC. | $65.22 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $60.58 | 2022-2023 | Yescarta |
| G1 Therapeutics, INC. | $55.71 | 2022-2023 | Cosela |
| Clovis Oncology, INC. | $52.85 | 2019 | |
| Boston Scientific Corporation | $52.75 | 2023-2025 | Eluvia, Lux-Dx Insertable Cardiac Monitor, Jetstream Sc |
| Pharmaessentia USA Corporation | $51.36 | 2022-2024 | Besremi |
| Geron Corporation | $45.47 | 2025 | Rytelo |
| Epizyme, INC. | $40.21 | 2020-2022 | |
| Adaptive Biotechnologies Corporation | $36.44 | 2022-2024 | Clonoseq |
| Incyte Corporation | $34.65 | 2024-2025 | Jakafi |
| Teva Pharmaceuticals USA, INC. | $27.15 | 2019 | |
| Janssen Pharmaceuticals, INC | $24.53 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $24.49 | 2022-2023 | Ultomiris |
| Stemline Therapeutics INC. | $19.41 | 2025 | Orserdu |
| Blueprint Medicines Corporation | $18.54 | 2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.